Subsequent treatment with PPARδ agonists have been shown to reverse NAFLD pathogenesis by restoring glucose and fatty acid metabolism and restoration of GLUT2 gene expression. Here, SLC2A2 is linked to metabolic dysfunction-associated steatotic liver disease.